Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

2,07

 

EUR

 

+1,72 %

Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

5.012 investorer følger denne virksomhed
Sammenligne
+1,72%
+16,03%
-20,08%
+81,58%
-45,09%
-43,6%
-37,46%
-33,23%
-40,52%

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Læs mere
Markedsværdi
216,57 mio. EUR
Aktieomsætning
251,49 t EUR
P/E (adj.) (24e)
-7,28
EV/EBIT (adj.) (24e)
-8,45
P/B (24e)
-21,19
EV/S (24e)
55.184,05
Udbytteafkast, % (24e)
-
Coverage
Anbefaling
Akkumulér
Kursmål
2.80 EUR
Opdateret
11.12.2024
Disclaimer
Latest research

Latest analysis report

Released: 11.12.2024

Latest extensive report

Released: 23.08.2022

Finanskalender
27.2
2025

Årsrapport '24

21.3
2025

Generalforsamling '24

27.8
2025

Delårsrapport Q2'25

Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper
Analyse af
Antti Siltanen

Faron: Towards final read-out in March

Faron reported more detailed interim results of the BEXMAB study at the annual meeting of the American Society of Hematology (ASH). The company is on track for the important final read-out in March, as tolerability and overall response rate have remained at good levels.

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.